Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Investigation of Specific Protein/Markers in Patients With Osteoarthritis of the Knee Having a Total Knee Replacement

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: May 31, 2012
Last updated: June 26, 2012
Last verified: June 2012
The main purpose of the study is to better understand how specific proteins/markers in blood, urine, synovial fluid (a lubricating fluid secreted by the membrane lining the joints), and joint tissue are involved in osteoarthritis of the knee. The aim is to investigate if there is a correlation between x-ray results, specific proteins/markers and different types of pain in patients with osteoarthritis of the knee. The study consists of 3 visits over 3-20 days and the last visit will be the day of surgery.

Osteoarthritis of the Knee

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of Biomarkers in an Exploratory Study in Patients With Osteoarthritis of the Knee Undergoing Total Knee Replacement Surgery

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Proportion of patients with upregulation of IL-6 or the IL-6 signalling pathway in the knee. [ Time Frame: 3-20 days prior to day 1 (surgery) and day 1 (surgery) . ]

Secondary Outcome Measures:
  • Biomarkers in synovial fluid, synovial membrane, and cartilage. [ Time Frame: Day 1 (surgery). ]
  • Biomarkers in blood and urine. [ Time Frame: 3-20 days prior to day 1 (surgery) and day 1 (surgery). ]
  • Biomarkers by Magnetic Resonance Imaging (MRI). [ Time Frame: 1-5 days prior to day 1 (surgery). ]
  • Polymorphisms in 10 specific genes. [ Time Frame: 3-20 days prior to day 1 (surgery) or at any time in the study. ]
  • WOMAC (Western Ontario and McMaster Osteoarthritis Index) variables and NPQ (Neuropathic Pain Questionnaire) variables. [ Time Frame: 3-20 days prior to day 1 (surgery) and 1-5 days prior to day 1 (surgery). ]

    WOMAC consists of 3 subscales with a total of 24 questions regarding pain, stiffness and difficulty in performing daily activities. A VAS (Visual Analogue Scale) will be used for the patient to report the severity of the symptoms on the target knee. Endpoints are marked "No pain" (0 mm) and " Extreme pain" (100 mm) on a paper PRO (Patient Reported Outcome) questionnaire. The less pain scored the better outcome.

    NPQ accesses 12 different pain intensities. 0 represents no intensity and 100 represents worst intensity imaginable. The less intensity the better outcome.

Biospecimen Retention:   Samples With DNA
Whole blood, plasma, serum, urine, synovial fluid, synovial membrane, cartilage

Enrollment: 125
Study Start Date: December 2011
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Patients with osteoarthritis of the knee
Patients with osteoarthritis of the knee undergoing total knee replacement surgery.

Detailed Description:
Investigation of Biomarkers in an Exploratory Study in Patients with Osteoarthritis of the Knee Undergoing Total Knee Replacement Surgery

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary and secondary care clinics

Inclusion Criteria:

  • Patients who will undergo a total knee replacement due to osteoarthritis.
  • Symptoms of the knee for at least 6 months prior to study start.

Exclusion Criteria:

  • Key-hole surgery performed on target knee within 3 months prior to study start.
  • History of disorders in which part of the immune system is missing or defective.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01611441

Research Site
Montreal, Canada
Research Center
Newmarket, Canada
Research Site
Quebec, Canada
Research Site
Kungalv, Sweden
Research Site
Motala, Sweden
Research Site
Stockholm, Sweden
Sponsors and Collaborators
Study Director: Rolf Karlsten, MD, PHD AstraZeneca R&D Sodertalje, Sweden
  More Information

Responsible Party: AstraZeneca Identifier: NCT01611441     History of Changes
Other Study ID Numbers: D2285M00029
Study First Received: May 31, 2012
Last Updated: June 26, 2012

Keywords provided by AstraZeneca:
Osteoarthritis of the knee

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on April 28, 2017